Compare Enveric Biosciences Inc (ENVB) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Standard Lithium Ltd — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Standard Lithium Ltd trades at $1.63 (market cap $398.07M). The key difference: Standard Lithium Ltd is far larger — about 58.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 1,564,155). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Standard Lithium Ltd for 23 Days on average.
| ENVB | SLI | |
|---|---|---|
Market Cap | $6.80M | $398.07M |
Volume | 64,867 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $5.65 |
52-Week Low | $1.27 | $1.61 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | -$1.49M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Standard Lithium (SLI) trades at $1.615, down 2.12% today, with a bearish technical signal despite oversold RSI readings. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has achieved key project milestones including customer offtake agreements with LG Energy Solution and Trafigura. Analyst consensus remains strongly bullish with a $3.83 price target, reflecting optimism about the Arkansas lithium project's 2026 final investment decision.
The investment case hinges on successful execution of the South West Arkansas lithium project, which could transform SLI from development to production phase. Key risks include project delays, funding requirements, and lithium price volatility. With 100% analyst buy ratings and institutional backing from BlackRock and Amundi, the stock offers high-risk, high-reward potential for investors betting on North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
